Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.
DermTech, Inc. (symbol: DMTK) is a groundbreaking molecular diagnostic dermatology company dedicated to revolutionizing the diagnosis of skin conditions through innovative non-invasive testing. Located at their CLIA-licensed laboratory in La Jolla, CA, DermTech operates at the cutting edge of dermatological science.
DermTech's core technology focuses on gene expression tests that aid in the clinical diagnosis of skin cancer and other skin conditions. Their flagship product, the Pigmented Lesion Assay (PLA), allows for the analysis of skin biopsy samples using an adhesive patch. This method offers a significant advancement over traditional methods that rely on subjective visual diagnosis and invasive surgical biopsies, which are often prone to error and lead to unnecessary procedures.
The PLA test is designed to detect melanoma in clinically atypical pigmented lesions with high accuracy, providing physicians with critical, objective data to enhance patient care and reduce healthcare costs. By utilizing DermTech’s non-invasive approach, patients experience enhanced comfort and safety during the diagnostic process.
DermTech is committed to advancing the field of dermatology through continuous innovation. In addition to their focus on skin cancer, the company is developing genomic tests to diagnose inflammatory skin diseases and conditions related to aging. These efforts are aimed at providing comprehensive solutions that improve the accuracy of diagnoses and overall patient outcomes.
With a strong emphasis on scientific development and patient care, DermTech partners with various healthcare providers and institutions to expand the availability of their tests. The company generates revenue through their laboratory services, ensuring a sustainable business model while aiming for growth and expanded impact in the dermatology field.
DermTech, a leader in precision dermatology, announced the launch of its expanded service, DermTech Stratum™. This service employs DermTech’s non-invasive technology for precision biomarker analysis, enhancing dermatologic disease diagnosis and treatment. Utilizing the Smart Sticker™, DermTech Stratum facilitates painless skin sample collection for genomic and proteomic studies. The service supports drug discovery efforts in cancers and inflammatory diseases, emphasizing personalized patient care and improved therapeutic outcomes. CEO Michael Howell highlighted the innovation aimed at advancing diagnostic tools for enhanced skin health.
DermTech (NASDAQ: DMTK) announced its participation in the Dermatology Drug Development Summit in Boston, presenting innovative approaches to non-invasive precision dermatology. The session, led by Michael D. Howell, PhD, focused on personalized dermatology via multi-omic analyses and biomarker identification using DermTech's Smart Sticker™. This technology allows for non-invasive skin assessments, enhancing the identification and treatment of chronic inflammatory skin conditions.
DermTech (DMTK) reported third quarter 2021 financial results, showing significant growth. Billable sample volume rose 75% YoY to approximately 11,720. Assay revenue reached $3.0 million, up 140% YoY, while total revenue also increased by 122% to $3.0 million. Gross margin improved to 4% from negative 18% a year prior. The net loss widened to $20.1 million, or $0.68 per share. Cash and equivalents totaled $252.5 million. Despite a revision in full-year assay revenue guidance to $10.5-$12.0 million due to unforeseen challenges, this still reflects robust growth compared to 2020.
DermTech (NASDAQ: DMTK) has partnered with DermatologistOnCall to provide the DermTech Melanoma Test via its telemedicine platform. This innovative agreement allows millions of patients to access non-invasive melanoma testing and early detection, critical for combating skin cancer deaths. Patients can collect samples at home using the DermTech Smart Sticker™, with results typically available within 10 days—much faster than traditional appointments. The test is affordable, with Medicare coverage and low out-of-pocket costs, enhancing access to dermatology care across the U.S.
DermTech, Inc. (NASDAQ: DMTK) announced its participation in key upcoming conferences. The company will present at the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021, and at the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 1:30 p.m. Eastern Time. Interested parties can access the live webcast and archived presentations on DermTech’s website, enhancing transparency for investors. As a leader in precision dermatology, DermTech focuses on non-invasive skin genomics to improve patient care.
DermTech, Inc. (NASDAQ: DMTK) will release its third quarter 2021 financial results on November 9, 2021, following market closure. A conference call will be held at 1:30 p.m. Pacific time to discuss the results and recent highlights. Interested participants can join via telephone or access the live webinar on DermTech's investor website. DermTech focuses on precision dermatology using a non-invasive skin genomics platform, aiming to enhance early detection of skin cancers and tailor drug treatments.
DermTech (NASDAQ: DMTK) participated in the inaugural Alliance for Innovation in Integrated Healthcare Summit on October 11, 2021. Senior VP Dan Visage was part of a panel discussing the impact of technology in dermatologic treatments.
The summit gathered leaders from various sectors to address challenges in healthcare innovation. DermTech aims to enhance precision dermatology through its non-invasive skin genomics platform.
DermTech, a leader in precision dermatology, has appointed Nathalie Gerschtein Keraudy, President of the Consumer Products Division at L’Oréal, to its board of directors. With over 20 years of experience at L’Oréal, where she oversees a division generating over
DermTech (NASDAQ: DMTK), a leader in precision dermatology, announced its sponsorship of the San Diego Open ATP 250 tournament and a partnership with tennis pro Brandon Nakashima. This initiative is aimed at raising awareness about sun safety and skin checks to facilitate early melanoma detection. The event runs from September 27 to October 3, 2021, and DermTech will educate attendees on skin health. Nakashima, a DermTech ambassador, emphasizes the importance of skin checks, advocating for the DermTech Melanoma Test.
DermTech (NASDAQ: DMTK) has announced that a significant study published in SKIN: The Journal of Cutaneous Medicine demonstrates the efficacy of its Pigmented Lesion Assay (PLA) in improving melanoma diagnostics. The TRUST study, involving 2,575 lesions, reveals the PLA achieves a negative predictive value (NPV) exceeding 99% and a real-world positive predictive value (PPV) of 18.7%. This approach reduces unnecessary biopsies while enhancing melanoma detection, showcasing DermTech's innovative contributions to precision dermatology.
FAQ
What is the current stock price of DermTech (DMTK)?
What is the market cap of DermTech (DMTK)?
What does DermTech, Inc. specialize in?
How does DermTech's Pigmented Lesion Assay (PLA) work?
Where is DermTech, Inc. located?
What makes DermTech's diagnostic method unique?
What other skin conditions does DermTech focus on?
How does DermTech improve patient care?
Is DermTech's technology widely available?
How does DermTech generate revenue?
What is DermTech's mission?
What recent achievements has DermTech made?
